Table 2.
Clinical characteristics of MF patients before the third dose of mRNA vaccine anti SARS-CoV-2.
| Clinical characteristics | MF Whole cohort (n = 19) | MF with ruxolitinib (n = 8) | MF without ruxolitinib (n = 11) |
|---|---|---|---|
| BMI (Kg/m2), median (range) |
21,3 (17,5–26,2) |
21,2 (18,5–25,1) |
21,7 (17,5–26,2) |
| Disease Primary MF Post–PV Post–ET |
12 (63.2%) 5 (26.3%) 2 (10.5%) |
3 (37.5%) 4 (50%) 1 (12.5%) |
9 (82%) 1 (9%) 1 (9%) |
| IPSS SCORE LOW INT–1 INT–2 HIGH |
4 (21%) 8 (42.1%) 4(21.1%) 3 (15.8%) |
1 (12.5%) 4 (50%) 1 (12.5%) 2 (25%) |
3 (27%) 4 (37%) 3 (27%) 1 (9%) |
| Driver mutation JAK2 CALR MPL Triple negative |
13 (69.1%) 5 (21.4%) 0 (0%) 1 (7.1%) |
8 (100%) 0 (0%) 0 (0%) 0 (0%) |
5 (45.5%) 5 (45.5%) 0 (0%) 1 (9%) |
| Exposition to ruxolitinib, months median (range) | 20.5 (6–42) |
||
| Spleen below costal margin, cm median (range) | 6.5 (0–22) |
12 (0–22) |
5 (0–13) |
| Hemoglobin g/dL, median (range) |
13 (8.6–14.8) |
13 (9.5–13.4) |
13 (8.6–14.8) |
| Platelets × 103/µL, median (range) |
395 (27–781) |
183 (27–680) |
458 (60–781) |
| WBC × 103/µL, median (range) |
9.45 (3.6–33.9) |
16.3 (3.6–33.9) |
9.45 (4.3–13.7) |
| Lymphocytes × 103/µL, median (range) | 1.76 (0.93–6.02) |
1.44 (1.07–6.02) |
1.8 (0.93–3.79) |
| Total protein g/dL, median (range) |
6.7 (5.7–7.9) |
6.4 (6–7.9) |
6.8 (5.7–7.1) |
| γ-Globulins (%), median (range) |
15.2 (7.3–23.3) |
15.2 (14.1–23.3) |
14.6 (7.3–19.9) |
| LDH U/L, median (range) |
422 (191–1384) |
391 (235–838) |
443 (191–1384) |
BMI, Body Mass Index; PMF, Primary Myelofibrosis; PV, Polycythemia vera; ET, Essential Thrombocythemia; WBC, White Blood Count (x103/µL); LDH, Lactate Dehydrogenase (U/L).